

DAFTAR PUSTAKA

- Anggita.T. Nuari & Masturoh I, 2018, *Metodologi Penelitian Kesehatan*: Jakarta.
- Alaydrus, S., 2020, Analisis biaya pengobatan penyakit paru obstruktif kronik pasien rawat inap rumah sakit umum daerah kabupaten sukoharjo. *Jurnal Ilmiah Farmasi Farmasyifa*, 3(1):51-61.
- Alison, J.A., McKeough, Z.J., Johnston, K., McNamara, R.J., Spencer, L.M., Jenkins, S.C., Hill, C.J., McDonald, V.M., Frith, P., Cafarella, P. dan Brooke, M., 2017. Australian and New Zealand Pulmonary Rehabilitation Guidelines. *Respirology*, 22(4):800-819.
- American Academy of Family Physicians, 2016, *COPD and Asthma: Differential Diagnosis*, Boehringer Ingelheim Pharmaceuticals.
- American Lung Association, 2018, *The Connection Between Pneumonia and Lung Disease*, <https://www.lung.org/blog/pneumonia-and-lung-disease#:~:text=COPD%20and%20asthma%20can%20cause,to%20infections%20Diakses%20pada%2025%20November%202023%20pukul%209.51> Diakses pada 25 November 2023 pukul 9.51
- Australian Institute of Health dan Welfare (AIHW), 2023, COPD, <https://www.aihw.gov.au/reports/chronic-respiratory-conditions/copd> diakses pada 1 September 2023 pukul 14.30 WIB.
- Bartlett, R.H., Ogino, M.T., Brodie, D., McMullan, D.M., Lorusso, R., MacLaren, G., Stead, C.M., Rycus, P., Fraser, J.F., Belohlavek, J. dan Salazar, L., 2020. Initial ELSO guidance document: ECMO for COVID-19 patients with severe cardiopulmonary failure. *Asaio Journal*, 66(5):472--474.
- Bertoletti, L., Quenet, S., Laporte, S., Sahuquillo, J.C., Conget, F., Pedrajas, J.M., Martin, M., Casado, I., Riera-Mestre, A., Monreal, M. dan RIETE Investigators riete@shmedical.es, 2013. Pulmonary embolism and 3-month outcomes in 4036 patients with venous thromboembolism and chronic obstructive pulmonary disease: data from the RIETE registry. *Respiratory research*, 14:1-8.
- Bilton D, Jones AL, 2011, European Respiratory Monograph: Bronchiectasis, *European Respiratory Society* 52:1-10.
- Black, P.N., 2008. Role of antibiotics in the management of chronic obstructive pulmonary disease. *Expert Review of Respiratory Medicine*, 2(2), pp.235-243.
- Bonini, M. dan Usmani, O.S., 2015. The importance of inhaler devices in the treatment of COPD. *COPD Research and Practice*, 1(1), pp.1-9.
- Cazzola, M., Rogliani, P., Ruggeri, P., Segreti, A., Proietto, A., Picciolo, S. dan Matera, M.G., 2013, Chronic treatment with indacaterol and airway response to salbutamol in stable COPD. *Respiratory Medicine*, 107(6):848-853.

- Cerezo Lajas, A., Gutiérrez González, E., Llorente Parrado, C., Puente Maestu, L. dan de Miguel-Diez, J., 2018. Readmission due to exacerbation of COPD: associated factors. *Lung*, 196, pp.185-193.
- Chrystyn, H., Mulley, B.A. dan Peake, M.D., 1988. Dose response relation to oral theophylline in severe chronic obstructive airways disease. *British Medical Journal*, 297(6662):1506-1510.
- Cosío, B.G., Shafiek, H., Iglesias, A., Yanez, A., Córdova, R., Palou, A., Rodriguez-Roisin, R., Peces-Barba, G., Pascual, S., Gea, J. dan Sibila, O., 2016. Oral low-dose theophylline on top of inhaled fluticasone-salmeterol does not reduce exacerbations in patients with severe COPD: a pilot clinical trial. *Chest*, 150(1):123-130.
- Cukic, V., Lovre, V., Dragisic, D. dan Ustamujic, A., 2012. Asthma and chronic obstructive pulmonary disease (COPD)—differences and similarities. *Materia socio-medica*, 24(2), p.100.
- Devereux, G., Cotton, S., Fielding, S., McMeekin, N., Barnes, P.J., Briggs, A., Burns, G., Chaudhuri, R., Chrystyn, H., Davies, L. dan De Soyza, A., 2018. Effect of theophylline as adjunct to inhaled corticosteroids on exacerbations in patients with COPD: a randomized clinical trial. *Jama*, 320(15):1548-1559.
- Dhand, R., Dolovich, M., Chipps, B., R. Myers, T., Restrepo, R. dan Rosen Farrar, J., 2012. The role of nebulized therapy in the management of COPD: evidence and recommendations. COPD: *Journal of Chronic Obstructive Pulmonary Disease*, 9(1), pp.58-72.
- DiPiro, Yee, G. C., Posey, M., Haines, S. T., Nolin, T. D., Ellingrod, V., 2015, *Pharmacotherapy A Pathophysiology Approach*, Ninth Ed.,
- Dull, R. dan Dull, S., 2020. Redundant medication use during acute exacerbation of chronic obstructive pulmonary disease in hospitalized patients. *International Journal of Clinical Pharmacy*, 42, pp.1278-1285.
- Ekström, M., Ahmadi, Z., Bornefalk-Hermansson, A., Abernethy, A. dan Currow, D., 2016. Oxygen for breathlessness in patients with chronic obstructive pulmonary disease who do not qualify for home oxygen therapy. *Cochrane database of systematic reviews*, (11).
- Elmenawi, K.A., Anil, V., Gosal, H., Kaur, H., Ngassa, H.C. and Mohammed, L., 2021. The Importance of Measuring Troponin in Chronic Obstructive Pulmonary Disease Exacerbations: A Systematic Review. *Cureus*, 13(8).
- Fimognari, F.L., Loffredo, L., Di Simone, S., Sampietro, F., Pastorelli, R., Monaldo, M., Violi, F. dan D'angelo, A., 2009. Hyperhomocysteinaemia and poor vitamin B status in chronic obstructive pulmonary disease. *Nutrition, Metabolism and Cardiovascular Diseases*, 19(9), pp.654-659.
- Geake, J.B., Dabscheck, E.J., Wood-Baker, R. dan Cates, C.J., 2015. Indacaterol, a once-daily beta 2-agonist, versus twice-daily beta 2-agonists or placebo for

- chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews*, (1).
- Ghen, Y.H., Yao, W.Z., Cai, B.Q., Hong, W.A.N.G., Deng, X.M., Gao, H.L., Huang, J.S. and Wang, X.M., 2008. Economic analysis in admitted patients with acute exacerbation of chronic obstructive pulmonary disease. *Chinese medical journal*, 121(7), pp.587-591.
- GINA, 2023, *Global Strategy for Asthma Management and Prevention*, USA: Global Initiative for Asthma.
- GOLD, 2023, *Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease*, USA: Global Initiative for Chronic Obstructive Lung Disease, Inc.
- Gutiérrez Villegas, C., Paz-Zulueta, M., Herrero-Montes, M., Parás-Bravo, P. and Madrazo Pérez, M., 2021, Cost analysis of chronic obstructive pulmonary disease (COPD): a systematic review. *Health Economics Review*, 11(1):1-12.
- Gwee, K. A., Goh, V., Lima, G., dan Setia, S. 2018. Coprescribing proton-pump inhibitors with nonsteroidal anti-inflammatory drugs: risks versus benefits. *Journal of pain research*, 11, 361–374. <https://doi.org/10.2147/JPR.S156938>
- Hardiyanti, T., Yasin, N.M. dan Andayani, T.M., 2021. Pengaruh Readmisi Terhadap Biaya pada Pasien PPOK Eksaserbasi Akut dan Faktor-Faktor yang Mempengaruhinya. *Majalah Farmaseutik*, 17(3), pp.398-405.
- Hasaini, A., 2020. Lama menderita dengan kualitas hidup pasien PPOK. *Journal of Nursing Invention*, 1(1), pp.1-8.
- Herse, F., Kiljander, T. dan Lehtimäki, L., 2015. Annual costs of chronic obstructive pulmonary disease in Finland during 1996–2006 and a prediction model for 2007–2030. *NPJ primary care respiratory medicine*, 25(1):1-6.
- Iheanacho, I., Zhang, S., King, D., Rizzo, M. and Ismaila, A.S., 2020, Economic burden of chronic obstructive pulmonary disease (COPD): a systematic literature review. *International journal of chronic obstructive pulmonary disease*, 15:439-460.
- Kaffah, S., Yuniadi, Y. dan Samoedro, E. 2016. Atrial Fibrillation in Chronic Obstruktive Pulmonary Disease, *Indonesian Journal of Cardiology*, 36(2), pp. 94-110. doi: 10.30701/ijc.v36i2.464.
- Kahnert, K., Lucke, T., Huber, R.M., Behr, J., Biertz, F., Vogt, A., Watz, H., Alter, P., Fähndrich, S., Bals, R. dan Holle, R., 2017. Relationship of hyperlipidemia to comorbidities and lung function in COPD: results of the COSYCONET cohort. *PLoS One*, 12(5), p.e0177501.
- Karner, C., Chong, J. dan Poole, P., 2014. Tiotropium versus placebo for chronic obstructive pulmonary disease. *Cochrane database of systematic reviews*, (7).

- Kementerian Kesehatan Republik Indonesia (Kemenkes RI), 2013, *Pedoman Penerapan Kajian Farmakoekonomi, 1-3*, Kementerian Kesehatan Republik Indonesia, Jakarta.
- Kementerian Kesehatan Republik Indonesia, 2018, *Riset Kesehatan Dasar (RISKESDAS)*, Jakarta: Kemenkes Republik Indonesia.
- Kemenkes, 2019, Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/687/2019 tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Penyakit Paru Obstruktif Kronik.
- Kew, K.M., Mavergames, C. dan Walters, J.A., 2013. Long-acting beta 2-agonists for chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews*, (10).
- Kim, V. dan Criner, G.J., 2013. Chronic bronchitis and chronic obstructive pulmonary disease. *American journal of respiratory and critical care medicine*, 187(3), pp.228-237.
- Lee, A.L. dan Goldstein, R.S., 2015. Gastroesophageal reflux disease in COPD: links and risks. *International journal of chronic obstructive pulmonary disease*, pp.1935-1949.
- Li, M., Wang, F., Chen, R., Liang, Z., Zhou, Y., Yang, Y., Chen, S., Ung, C.O.L. and Hu, H., 2018. Factors contributing to hospitalization costs for patients with COPD in China: a retrospective analysis of medical record data. *International journal of chronic obstructive pulmonary disease*, pp.3349-3357.
- Lin, S.M., Liu, K.X., Lin, Z.H. dan Lin, P.H., 2017, Does high-flow nasal cannula oxygen improve outcome in acute hypoxemic respiratory failure? A systematic review and meta-analysis. *Respiratory medicine*, 131:58-64.
- Lipson, D.A., Barnhart, F., Brealey, N., Brooks, J., Criner, G.J., Day, N.C., Dransfield, M.T., Halpin, D.M., Han, M.K., Jones, C.E. dan Kilbride, S., 2018. Once-daily single-inhaler triple versus dual therapy in patients with COPD. *New England Journal of Medicine*, 378(18):1671-1680.
- Liza, Y. dan Mentari, L., 2020. Komplikasi dan Komorbid pada Pasien Diabetik Ketoasidosis.
- Lwanga, S.K., dan Limeshow, S. 1997. *Sample Size Determination for Health Studies: A Practical Manual*. Geneva: World Health Organization (WHO).
- Maltais, F., Bjermer, L., Kerwin, E.M., Jones, P.W., Watkins, M.L., Tombs, L., Naya, I.P., Boucot, I.H., Lipson, D.A., Compton, C. dan Vahdati-Bolouri, M., 2019. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. *Respiratory research*, 20(1),:1-15.
- Mulpuru, S., McKay, J., Ronksley, P.E., Thavorn, K., Kobewka, D.M. dan Forster, A.J., 2017. Factors contributing to high-cost hospital care for patients with

COPD. *International journal of chronic obstructive pulmonary disease*, pp.989-995.

Marchetti, N. dan Criner, G.J., 2015, August. Surgical approaches to treating emphysema: lung volume reduction surgery, bullectomy, and lung transplantation. In *Seminars in respiratory and critical care medicine*, 36(04): 592-608.

Martinez, F.J., Calverley, P.M., Goehring, U.M., Brose, M., Fabbri, L.M. dan Rabe, K.F., 2015. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. *The Lancet*, 385(9971):857-866.

McKay, S.E., Howie, C.A., Thomson, A.H., Whiting, B. dan Addis, G.J., 1993. Value of theophylline treatment in patients handicapped by chronic obstructive lung disease. *Thorax*, 48(3):227-232.

McKeever, T.M., Hearson, G., Housley, G., Reynolds, C., Kinnear, W., Harrison, T.W., Kelly, A.M. dan Shaw, D.E., 2016, Using venous blood gas analysis in the assessment of COPD exacerbations: a prospective cohort study. *Thorax*, 71(3):210-215.

Melani, A.S., 2015. Long-acting muscarinic antagonists. *Expert review of clinical pharmacology*, 8(4):.479-501.

Miravittles, M., Kruesmann, F., Haverstock, D., Perroncel, R., Choudhri, S.H. and Arvis, P., 2012. Sputum colour and bacteria in chronic bronchitis exacerbations: a pooled analysis. *European Respiratory Journal*, 39(6) : 1354-1360.

Najihah, N., Theovena, E.M., Ose, M.I. dan Wahyudi, D.T., 2023. Prevalensi Penyakit Paru Obstruksi Kronik (PPOK) Berdasarkan Karakteristik Demografi dan Derajat Keparahan. *Journal of Borneo Holistic Health*, 6(1).

NIH, 2022, What is COPD? <https://www.nhlbi.nih.gov/health/copd> diakses pada 1 September 2023 pukul 13.18 WIB.

Nurfitriani, N. dan Ariesta, D.M., 2021. FAKTOR-FAKTOR YANG MEMPENGARUHI KEJADIAN PENYAKIT PARU OBSTRUKTIF KRONIK (PPOK) PADA PASIEN POLIKLINIK PARU DI RSUD MEURAXA. *Jurnal Sains Riset*, 11(2), pp.458-462.

O'donnell, D.E., Flüge, T., Gerken, F., Hamilton, A., Webb, K., Aguilaniu, B., Make, B. dan Magnussen, H., 2004. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. *European Respiratory Journal*, 23(6):832-840.

O'Donnell, D.E., Sciurba, F., Celli, B., Mahler, D.A., Webb, K.A., Kalberg, C.J. dan Knobil, K., 2006. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. *Chest*, 130(3):647-656.

- Oemiaty, R., 2013. Kajian epidemiologis penyakit paru obstruktif kronik (PPOK). *Media Penelitian dan Pengembangan Kesehatan*, 23(2):20807.
- PDPI, 2021, *PPOK: Pedoman Diagnosa dan Penatalaksanaan di Indonesia*, Jakarta: PDPI
- Poole, P., Sathananthan, K. dan Fortescue, R., 2019. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews*, 5(5).
- Pothirat, C., Chaiwong, W., Limsukon, A., Deesomchok, A., Liwsrisakun, C., Bumroongkit, C., Theerakittikul, T. and Phetsuk, N., 2015. Detection of acute deterioration in health status visit among COPD patients by monitoring COPD assessment test score. *International Journal of Chronic Obstructive Pulmonary Disease*, pp.277-282.
- Rabe, K.F., Calverley, P.M., Martinez, F.J. dan Fabbri, L.M., 2017. Effect of roflumilast in patients with severe COPD and a history of hospitalisation. *European Respiratory Journal*, 50(1).
- Rascati, K.L., 2014, *Essentials of Pharmacoeconomics*. 2nd Edition. Philadelphia: Wolters Kluwer Health/Lippincott Williams dan Wilkins.
- Ray, R., Tombs, L., Naya, I., Compton, C., Lipson, D.A. dan Boucot, I., 2019. Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: a pooled post hoc analysis of seven clinical trials. *Pulmonary Pharmacology & Therapeutics*, 57:101802.
- Rinne, S. T., Graves, M. C., Bastian, L. A., Lindenauer, P. K., Wong, E. S., Hebert, P. L., dan Liu, C. F. 2017. Association between length of stay and readmission for COPD. *The American journal of managed care*, 23(8), e253–e258.
- Roca, O., Hernández, G., Díaz-Lobato, S., Carratalá, J.M., Gutiérrez, R.M., Masclans, J.R. dan Spanish Multidisciplinary Group of High Flow Supportive Therapy in Adults (HiSpaFlow), 2016, Current evidence for the effectiveness of heated and humidified high flow nasal cannula supportive therapy in adult patients with respiratory failure. *Critical care*, 20(10):1-13.
- RS Respira, 2021, <https://rsprespira.jogjaprovo.go.id/wp-content/uploads/2021/08/SK-PENETAPAN-RUANG-TT-PASIEN-RANAP-RS-PARU-RESPIRA.pdf>, diakses pada 25 November 2023.
- Sarkar, M., Srinivasa, Madabhavi, I. dan Kumar, K., 2017. Tuberculosis associated chronic obstructive pulmonary disease. *The Clinical Respiratory Journal*, 11(3), pp.285-295.
- Sivapalan, P., Ingebrigtsen, T.S., Rasmussen, D.B., Sørensen, R., Rasmussen, C.M., Jensen, C.B., Allin, K.H., Eklöf, J., Seersholm, N., Vestbo, J. dan Jensen, J.U.S., 2019, COPD exacerbations: the impact of long versus short courses of oral corticosteroids on mortality and pneumonia: nationwide data on 67 000 patients

- with COPD followed for 12 months. *BMJ open respiratory research*, 6(1), p.e000407.
- Siyoto, S. dan Sodik A., 2015, *Dasar Metodologi Penelitian*, Yogyakarta: Literasi Media Publishing.
- Søgaard, M., Madsen, M., Løkke, A., Hilberg, O., Sørensen, H.T. dan Thomsen, R.W., 2016. Incidence and outcomes of patients hospitalized with COPD exacerbation with and without pneumonia. *International journal of chronic obstructive pulmonary disease*, pp.455-465.
- Spruit, M.A., Singh, S.J., Garvey, C., ZuWallack, R., Nici, L., Rochester, C., Hill, K., Holland, A.E., Lareau, S.C., Man, W.D.C. dan Pitta, F., 2013, An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. *American journal of respiratory and critical care medicine*, 188(8):e13-e64.
- Suastika n. K. W., Aryana I. G. P. S., Kuswardhani R. A. T., 2015, Korelasi Negatif antara Charlson Comorbidity Index dengan Jumlah Limfosit Total dan Kadar Albumin pada Pasien Geriatri, *Jurnal Ilmiah Kedokteran Medicina* 46(3).
- Sugiyono 2016, *Metode Penelitian Kuantitatif, Kualitatif dan R&D*. Edisi ke 26. Alfabeta.
- Susanto, A.D., 2021, Permasalahan Penyakit Paru Obstruktif Kronik (PPOK) Pada Pekerja. *Jurnal Respirologi Indonesia*, 41(1):.64-73.
- Walters, J.A., Tan, D.J., White, C.J., Gibson, P.G., Wood-Baker, R. dan Walters, E.H., 2014. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews*, (9).
- Walters, J.A., Tan, D.J., White, C.J. dan Wood-Baker, R., 2018. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews*, (3).
- Williams, D.M., 2018. Clinical pharmacology of corticosteroids. *Respiratory care*, 63(6), pp.655-670.
- w, S., Budhraj, A., Nagdeote, S. T., Sharma, K., & Shanti Dausage, C. 2016. Assessment of length of hospital stays of patients with acute exacerbations of chronic obstructive pulmonary disease. *International Journal of Medical Research and Review*, 4(1), 97-103. <https://doi.org/10.17511/ijmrr.2016.i01.015>
- Trigueros, J.A., Garin, N., Balloira, A., Aceituno, S., Calvo, A., Prades, M., Touron, C., Martínez, A. dan Torres, C., 2022, Cost-effectiveness analysis of triple therapy with budesonide/glycopyrronium/formoterol fumarate versus dual therapy in patients with chronic obstructive pulmonary disease in Spain. *International Journal of Chronic Obstructive Pulmonary Disease*, 17:2905-2917.

- van der Hoeven, S.M., Binnekade, J.M., de Borgie, C.A., Bosch, F.H., Endeman, H., Horn, J., Juffermans, N.P., van der Meer, N.J., Merkus, M.P., Moeniralam, H.S. dan van Silfhout, B., 2015. Preventive nebulization of mucolytic agents and bronchodilating drugs in invasively ventilated intensive care unit patients (NEBULAE): study protocol for a randomized controlled trial. *Trials*, 16, pp.1-11.
- van Geffen, W.H., Douma, W.R., Slebos, D.J. and Kerstjens, H.A., 2016. Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD. *Cochrane Database of Systematic Reviews*, (8).
- van Isselt, E.F.V.D., Groenewegen-Sipkema, K.H., Spruit-van Eijk, M., Chavannes, N.H., De Waal, M.W., Janssen, D.J. dan Achterberg, W.P., 2014. Pain in patients with COPD: a systematic review and meta-analysis. *BMJ open*, 4(9), p.e005898.
- Vestbo, J., Hurd, S.S., Agustí, A.G., Jones, P.W., Vogelmeier, C., Anzueto, A., Barnes, P.J., Fabbri, L.M., Martinez, F.J., Nishimura, M. dan Stockley, R.A., 2013. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *American journal of respiratory and critical care medicine*, 187(4):347-365.
- Wang, Y., Stavem, K., Dahl, F. A., Humerfelt, S., & Haugen, T. 2014. Factors associated with a prolonged length of stay after acute exacerbation of chronic obstructive pulmonary disease (AECOPD). *International journal of chronic obstructive pulmonary disease*, 9, 99–105. <https://doi.org/10.2147/COPD.S51467>.
- Wilson, M.E., Dobler, C.C., Morrow, A.S., Beuschel, B., Alsawas, M., Benkhadra, R., Seisa, M., Mittal, A., Sanchez, M., Daraz, L. dan Holets, S., 2020. Association of home noninvasive positive pressure ventilation with clinical outcomes in chronic obstructive pulmonary disease: a systematic review and meta-analysis. *Jama*, 323(5):455-465.
- Wootton, S.L., Hill, K., Alison, J.A., Ng, L.W.C., Jenkins, S., Eastwood, P.R., Hillman, D.R., Jenkins, C., Spencer, L.M., Cecins, N. dan McKeough, Z.J., 2019. Effects of ongoing feedback during a 12-month maintenance walking program on daily physical activity in people with COPD. *Lung*, 197:315-319.
- World Health Organisation, 2023, Chronic Respiratory Diseases: Burden of COPD. <https://www.who.int/respiratory/copd/burden/en/> Diakses pada 27 Agustus 2023 pukul 17.00 WIB.
- Wu M, Zhao Q, Chen Y, Fu C, Xu B. 2015, Quality of life and its association with direct medical costs for COPD in urban China, *Health Qual Life Outcomes*, 26:439-460.
- Wulandari, A., 2020, Analisis Biaya Terapi Pasien Penyakit Paru Obstruktif Kronik (PPOK) Rawat Inap di RSUP Fatmawati Periode 2018. *Saintech Farma*, 13(1):8—14.

- Yasir M, Goyal A, Sonthalia S., 2022, *Corticosteroid Adverse Effects*, Island (FL): StatPearls Publishing; <https://www.ncbi.nlm.nih.gov/books/NBK531462/> diakses pada 25 November 2023 pukul 9.57 WIB.
- Yonata, A., 2016. Pengaruh Komorbid terhadap Terjadinya Bakterimia MDR Gram Negatif pada Pasien Rawat Inap. *JK Unila*, 1(2), pp.211-214.
- Yu, C., Xia, Q., Li, Q., Wu, J., Wang, X. dan Wu, J., 2023. Hospitalization costs of COPD cases and its associated factors: an observational study at two large public tertiary hospitals in Henan Province, China. *BMC geriatrics*, 23(1), p.457.